IBIO · iBio Inc
United States · RS rating 7 · As of 2026-10-14
| Price | 0.78 USD |
|---|---|
| 1-day change | +0.1% |
| RS rating (overall / 1M / 3M / 12M) | 7 / 5 / 7 / 39 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 19 / 15 / 38 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +18.2% |
| Sales growth Q/Q | -100.0% |
| Distance from 52-week high | +74.6% |
| Market cap (USD) | $65.4M |